Name: MEIRAGTX HOLDINGS PLC (MGTX) Stock
Brand: MEIRAGTX HOLDINGS PLC
Rating: 6 (3 reviews)

MGTX Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Zacks Investment Research - Mentions: TWST

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Lags Revenue Estimates

2 days ago - By: MeiraGTx

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

2 days ago - By: MeiraGTx

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

5 days ago - By: Stocktwits - Mentions: IWMW VTWG LLY

MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle?

5 days ago - By: Zacks Investment Research - Mentions: VYGR

Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates

5 days ago - By: Benzinga - Mentions: LLY

Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration

5 days ago - By: Benzinga - Mentions: SRDX WORX IONS GTBP ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

5 days ago - By: MeiraGTx

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

5 days ago - By: MeiraGTx

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

8 days ago - By: Zacks Investment Research - Mentions: ALEC

Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates

9 days ago - By: Zacks Investment Research - Mentions: GOSS

Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates

10 days ago - By: Zacks Investment Research - Mentions: XFOR

MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

a month ago - By: MeiraGTx

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

3 months ago - By: Zacks Investment Research - Mentions: CLNN

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: XLO

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: The Motley Fool

MeiraGTx Sales Jump 1,133 Percent

3 months ago - By: MeiraGTx

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

3 months ago - By: MeiraGTx

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

3 months ago - By: Zacks Investment Research - Mentions: IFRX

InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates

6 months ago - By: MeiraGTx

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

6 months ago - By: MeiraGTx

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

6 months ago - By: Zacks Investment Research - Mentions: AFMD

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates

6 months ago - By: MeiraGTx

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

6 months ago - By: MeiraGTx

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

6 months ago - By: MeiraGTx

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

6 months ago - By: MeiraGTx

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease

8 months ago - By: MeiraGTx

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

8 months ago - By: MeiraGTx

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

8 months ago - By: MeiraGTx

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

8 months ago - By: MeiraGTx

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

9 months ago - By: MeiraGTx

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

MEIRAGTX HOLDINGS PLC (MGTX) Stock News

MGTX Latest News, Press Relases and Analysis